Pfizer (Pfizer)

Lobbying Organisation Pfizer

Date published 20 Sep, 2019

Relevant Matter Public policy or programme

Public Policy Area Health

Period 1 May, 2019 to 31 Aug, 2019

Specific Details Ireland has become one of the slowest countries in Europe to reimburse innovative medicines for patients, now ranking 16th out of 26th according to EFPIA.

Intended results Highlight our concerns that Ireland is slow in reimbursing new medicines compared with other countries.

Name of person primarily responsible for lobbying on this activity Karen O'Keeffe

Did any Designated Public Official(DPO) or former Designated Public Official(DPO) carry out lobbying activities on your behalf in relation to this return? You must include yourself, and answer Yes, if you are a current DPO or a DPO at any time in the past. (What is a Designated Public Official?) No

Did you manage or direct a grassroots campaign? No

Was this lobbying done on behalf of a client? No

Lobbying activity

The following activities occurred for this specific Subject Matter Area.

Meeting (1)

meeting with Minister Humphries at Pfizer Ringaskiddy site

Event / Reception (1)

Discussion at the launch of the Pfizer Health & Science Index in the Royal College of Surgeons

Email (2-5)

Email invitation to event in RCSI and email correspondence to arrange meeting at Ringaskiddy

Phone call (2-5)

phone calls to arrange logistics re Ringaskiddy meeting with Minister's office

Designated public officials lobbied

The following DPOs were lobbied during this return period on this specific Subject Matter Area. These DPOs were involved in at least one of the Lobbying Activities listed above, but not necessarily all of them. As returns are specific to a Subject Matter Area the above Lobbying Activities may be associated with multiple returns.

Heather Humphreys Minister (Department of Business, Enterprise and Innovation)

Michael Harty TD (Dáil Éireann, the Oireachtas)